What is CAGR? What does CAGR table indicate for Auromed Ltd?

Compounded average growth rate (CAGR) measures the average annual growth rate compounded year-on-year over a period of time.

Auromed Ltd Stock Analysis

Q: Is Auromed Ltd a good quality company?

MoneyWorks4Me analysed the past 10-year performance of Auromed Ltd and arrived at the following conclusion.

Q: Is the current market price of Auromed Ltd a good price to buy it?

The 5-year analysis of Auromed Ltd's performance infers.

Q: What is Auromed Ltd share price return in the past 10 years?

We analysed the performance of Auromed Ltd share prices over the last 10 years. Here is what we found out:

Small Cap

Evaluated by 4 users | BSE: 532103 | NSE: |
Pharmaceuticals & Drugs

10 Year X-Ray

Standalone basis Standalone basis P Consolidated basis

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

What is a Financial Track Record? How to read this chart in order to understand the data present here?

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

	Mar'02	Mar'03	Mar'04	Mar'05
Return on Capital Employed	0.03%	0.05%	0.2%	0.91%

Growth Parameters	Growth Parameters Colour Code Guide

Net Sales (Rs. Cr.)	0.4	0.4	0.4	1.5
Y-o-Y Gr. Rt.	-	8.1%	-2.5%	284.6%
Adjusted EPS (Rs.)	0	0.01	0.02	0.09
Y-o-Y Gr. Rt.	-	NA	100%	350%
Book Value per Share (Rs.)	9.36	9.37	9.58	9.76
Adjusted Net Profit	0	0	0	0.1
Net Op. Cash Flow (Rs. Cr.)	-0.1	0	-0.1	0.2
Debt to Cash Flow from Ops	-0.31	-1.06	-0.11	0.07

Difference between Standalone Basis and Consolidated basis? Which method is preferred for Auromed Ltd. ?

Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.

Auromed Ltd. should be analysed on a Standalone basis

CAGR CAGR Colour Code Guide

	9 yrs	5 yrs	3 yrs	1 yr
Net Sales	NA	NA	59.5%	284.6%
Adjusted EPS	NA	NA	NA	350%
Book Value per Share	0	0	1.4	1.9
Share Price	-	-	-	-

Key Financial Parameter	Performance Ratio Colour Code Guide

	Mar'02	Mar'03	Mar'04	Mar'05
Return on Equity (%)	0.03	0.05	0.19	0.91
Operating Profit Margin (%)	0.48	0.72	-6.31	6.61
Net Profit Margin (%)	0.29	0.44	2.13	3.12
Debt to Equity	0	0.01	0	0
Working Capital Days	0	160	218	71
Cash Conversion Cycle	0	57	91	31

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

FAQs

1. Is Auromed Ltd a good quality company?

Data is not available for this company.

2. Is current market price of Auromed Ltd a good price to buy it?

Data is not available for this company.

3. What is Auromed Ltd share price return in the past 10 years ?

Data is not available for this company

About Company

Auromed was incorporated in March 1995 as a public limited company promoted by D Srinivasvaradhan. The company is in the process of establishing a multipurpose bulk drug and pharmaceutical manufacturing plant at Guduvancheri in Tamilnadu. It came out with a public issue in June 1996 to part-finance this project. The company manufactures bronopol BP, norfloxacin BP and diclofenac sodium BP, betaine base and betaine hydrochloride BP.

Bronopol will be exported to

Bronopol will be exported to European countries for which the company has firm marketing tie-up with Transtech International, UK; Herman Gshutte & Co, Germany and Pharmaco, Germany. Betaine base and betaine hydrochloride will also be exported through marketing agreement with Perry Pharmaceuticals, UK; Lab-Tech Pharma, Switzerland and Webster Pharma Technique, France . Norfloxacin and diclofenac sodium will be marketed in the domestic market.

The registered office of the company is located at Srinilayam 1, Kannaiah Street, T Nagar Chennai in Tamil Nadu.

Read Less